Eliquis (apixaban) is an anticoagulant drug developed by Bristol-Myers Squibb and Pfizer that belongs to the group of direct factor Xa inhibitors[1][7]. The drug has been approved in the European Union for the prevention of venous thromboembolism after hip and knee surgery, as well as for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation[2][5]. Apixaban works by blocking factor Xa, which is an important component of the blood clotting process[7]. Eliquis sales are forecast to decline by 15.2% this year due to the loss of its exclusivity in the European market in May 2026[1]. Generic versions of apixaban have already entered the market, such as Apixaban Accord, which have the same potency as the original Eliquis[3]. The medicine is only available on prescription in the form of tablets with different doses[5].